Skip to search formSkip to main contentSkip to account menu

xemilofiban

Known as: 4-Pentynoic acid, 3-004-004-(((aminoiminomethyl)phenyl)amino)-((1,4-dioxobutyl)amino)-, ethyl ester, (S)-, ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidinesPlatelet Aggregation Inhibitors

Narrower (1)

SC 54684A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Demonstrative validation study employing a packed column pressurized fluid chromatography method that provides assay, achiral impurities, chiral impurity, and IR identity testing for a drug substance…
Review
2001
Review
2001
Future Perspectives for Optimizing Oral Antiplatelet Therapy
Secondary prevention of stroke and other manifestations of atherothrombosis is essential if the burden of disease associated with… 
2001
2001
Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagonists of this receptor cause a… 
2000
2000
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial… 
2000
2000
Highlights of the 49 th Scientific Sessions of the American College of Cardiology
Acute Coronary Syndromes The Trial: SYMPHONY II Presenter:Kristin Newby, Duke University Medical Center, Durham, NC. The study: A… 
2000
2000
Acute Coronary Syndromes The Trial : SYMPHONY II Presenter :
Acute Coronary Syndromes The Trial: SYMPHONY II Presenter:Kristin Newby, Duke University Medical Center, Durham, NC. The study: A… 
1999
1999
Design and Objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) Study
Clinical trials have demonstrated the efficacy of glycoprotein (GP) IIb/IIIa antagonists in preventing the thrombotic end points… 
1999
1999
Unstable Angina The Trial : FRISC II
Unstable Angina The Trial: FRISC II Presenters:Lars Wallentin and Bo Lagerqvist, Cardiothoracic Centre, University Hospital… 
1999
1999
Highlights Highlights of the 48 th Scientific Sessions of the American College of Cardiology
Unstable Angina The Trial: FRISC II Presenters:Lars Wallentin and Bo Lagerqvist, Cardiothoracic Centre, University Hospital… 
1997
1997
Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist
Platelet aggregation and thrombosis play an important role in the onset of acute coronary events. Regardless of the stimulus for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)